Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors
Overview
Authors
Affiliations
Epigenetic mechanisms are involved in regulating chromatin structure and gene expression through repression. In this study, we show that histone deacetylase inhibitors (DAIs) that alter the acetylation of histones in chromatin enhance the expression of several genes on tumor cells including: MHC class I, II, and the costimulatory molecule CD40. Enhanced transcription results in a significant increase in protein expression on the tumor cell surface, and expression can be elicited on some tumors that are unresponsive to IFN-gamma. The magnitude of induction of these genes cannot be explained by the effect of DAIs on the cell cycle or enhanced apoptosis. Induction of class II genes by DAIs was accompanied by activation of a repressed class II transactivator gene in a plasma cell tumor but, in several other tumor cell lines, class II was induced in the apparent absence of class II transactivator transcripts. These findings also suggest that the abnormalities observed in some tumors in the expression of genes critical to tumor immunity may result from epigenetic alterations in chromatin and gene regulation in addition to well-established mutational mechanisms.
Almawash S Cancers (Basel). 2025; 17(5).
PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.
MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.
Barbeau L, Beelen N, Savelkouls K, Keulers T, Wieten L, Rouschop K PLoS One. 2025; 20(2):e0316716.
PMID: 39928678 PMC: 11809862. DOI: 10.1371/journal.pone.0316716.
Yi K, Sun C, Yuan Y, Luo Z, Luo H, Xie Y Front Immunol. 2025; 16:1510650.
PMID: 39911383 PMC: 11794256. DOI: 10.3389/fimmu.2025.1510650.
Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M Cancers (Basel). 2024; 16(23).
PMID: 39682244 PMC: 11640654. DOI: 10.3390/cancers16234058.
Getting the right combination to break the epigenetic code.
Tolu S, Viny A, Amengual J, Pro B, Bates S Nat Rev Clin Oncol. 2024; 22(2):117-133.
PMID: 39623073 DOI: 10.1038/s41571-024-00972-1.